Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
National Cancer Institute (NCI)
Sapna P Patel; Megan Othus; Yuanbin Chen; G Paul Wright; Kathleen J Yost; John R Hyngstrom; Siwen Hu-Lieskovan; Christopher D Lao; Leslie A Fecher; Thach-Giao Truong; Jennifer L Eisenstein; Sunandana Chandra; Jeffrey A Sosman; Kari L Kendra; Richard C Wu; Craig E Devoe; Gary B Deutsch; Aparna Hegde; Maya Khalil; Ankit Mangla; Amy M Reese; Merrick I Ross; Andrew S Poklepovic; Giao Q Phan; Adedayo A Onitilo; Demet G Yasar; Benjamin C Powers; Gary C Doolittle; Gino K In; Niels Kokot; Geoffrey T Gibney; Michael B Atkins; Montaser Shaheen; James A Warneke; Alexandra Ikeguchi; Jose E Najera; Bartosz Chmielowski; Joseph G Crompton; Justin D Floyd; Eddy Hsueh; Kim A Margolin; Warren A Chow; Kenneth F Grossmann; Eliana Dietrich; Victor G Prieto; Michael C Lowe; Elizabeth I Buchbinder; John M Kirkwood; Larissa Korde; James Moon; Elad Sharon; Vernon K Sondak; Antoni Ribas